Menu

Blog

Mar 14, 2024

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

Posted by in categories: biotech/medical, neuroscience

Only 3% to 5% of people who are diagnosed with this type of brain tumor will be alive three years later. On average, patients live about 14 months after diagnosis.

Now, an experimental therapy that reprograms a person’s own immune cells to attack these tumors is showing some exciting promise.

Three studies published within the past week have reported dramatic results with a therapy called CAR-T delivered directly to the brain. In some cases, tumors have seemingly melted away on brain scans by the next day.

Comments are closed.